Kwality Pharmaceuticals has announced a board meeting to discuss the financial results for the quarter and half-year.

The company highlighted its leadership in complex injectables manufacturing, with a diverse product range including sterile powders, injectables, tablets, and biologics from its multiple state-of-the-art facilities.

Backed by 40+ years of experience, Kwality Pharma reported revenue growth to INR 370 Cr and a net profit of INR 40 Cr, aiming for INR 500 Cr in revenue with improving EBITDA margins.

The firm is advancing biologics development with regulatory filings and clinical trials underway, targeting global market expansion, especially in highly regulated regions.